用于微创治疗良性前列腺增生的Optilume BPH导管系统设备简介。

IF 2.7
Expert review of medical devices Pub Date : 2025-10-01 Epub Date: 2025-09-01 DOI:10.1080/17434440.2025.2553051
Mohammadali Saffarzadeh, Marcus Derigs, Runhan Ren, Naeem Bhojani, Dean Elterman, Connor M Forbes
{"title":"用于微创治疗良性前列腺增生的Optilume BPH导管系统设备简介。","authors":"Mohammadali Saffarzadeh, Marcus Derigs, Runhan Ren, Naeem Bhojani, Dean Elterman, Connor M Forbes","doi":"10.1080/17434440.2025.2553051","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Benign Prostatic Hyperplasia (BPH) can lead to Lower Urinary Tract Symptoms (LUTS) that worsen with age and impact quality of life. Minimally invasive Surgical Therapies (MISTs) provide an alternative to medical and surgical interventions for the treatment of LUTS. The Optilume BPH Catheter System is a MIST for LUTS, which is the focus of this review.</p><p><strong>Areas covered: </strong>The Optilume BPH Catheter System is a Food and Drug Administration (FDA)-approved MIST that utilizes balloon dilation and delivery of paclitaxel to the prostatic urethra to treat LUTS. This review evaluates the technology, utility, clinical evidence, safety profile, and long-term efficacy of Optilume BPH Catheter System, in the context of alternative options for management of LUTS. PubMed and Google Scholar were searched and all published articles and abstracts up to May 2025 related to Optilume BPH Catheter Systems were included in our review.</p><p><strong>Expert opinion: </strong>The Optilume BPH Catheter System is a promising MIST in the market with durable results and acceptable safety profile. Ongoing and future research will further refine its long-term safety and efficacy.</p>","PeriodicalId":94006,"journal":{"name":"Expert review of medical devices","volume":" ","pages":"1081-1091"},"PeriodicalIF":2.7000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Device profile of Optilume BPH Catheter System for minimally invasive treatment of benign prostatic hyperplasia.\",\"authors\":\"Mohammadali Saffarzadeh, Marcus Derigs, Runhan Ren, Naeem Bhojani, Dean Elterman, Connor M Forbes\",\"doi\":\"10.1080/17434440.2025.2553051\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Benign Prostatic Hyperplasia (BPH) can lead to Lower Urinary Tract Symptoms (LUTS) that worsen with age and impact quality of life. Minimally invasive Surgical Therapies (MISTs) provide an alternative to medical and surgical interventions for the treatment of LUTS. The Optilume BPH Catheter System is a MIST for LUTS, which is the focus of this review.</p><p><strong>Areas covered: </strong>The Optilume BPH Catheter System is a Food and Drug Administration (FDA)-approved MIST that utilizes balloon dilation and delivery of paclitaxel to the prostatic urethra to treat LUTS. This review evaluates the technology, utility, clinical evidence, safety profile, and long-term efficacy of Optilume BPH Catheter System, in the context of alternative options for management of LUTS. PubMed and Google Scholar were searched and all published articles and abstracts up to May 2025 related to Optilume BPH Catheter Systems were included in our review.</p><p><strong>Expert opinion: </strong>The Optilume BPH Catheter System is a promising MIST in the market with durable results and acceptable safety profile. Ongoing and future research will further refine its long-term safety and efficacy.</p>\",\"PeriodicalId\":94006,\"journal\":{\"name\":\"Expert review of medical devices\",\"volume\":\" \",\"pages\":\"1081-1091\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert review of medical devices\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17434440.2025.2553051\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/9/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert review of medical devices","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17434440.2025.2553051","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:良性前列腺增生(BPH)可导致下尿路症状(LUTS),随着年龄的增长而恶化并影响生活质量。微创手术治疗(mist)为治疗LUTS提供了一种替代药物和手术干预的方法。Optilume BPH导管系统是一种用于LUTS的MIST,这是本综述的重点。覆盖领域:Optilume BPH导管系统是美国食品和药物管理局(FDA)批准的MIST,利用球囊扩张和向前列腺尿道输送紫杉醇来治疗LUTS。这篇综述评估了Optilume BPH导管系统的技术、实用性、临床证据、安全性和长期疗效,作为治疗LUTS的备选方案。检索PubMed和谷歌Scholar,截至2025年5月,所有与Optilume BPH导管系统相关的已发表文章和摘要均纳入我们的综述。专家意见:Optilume BPH导管系统是市场上很有前途的MIST,具有持久的效果和可接受的安全性。正在进行和未来的研究将进一步完善其长期安全性和有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Device profile of Optilume BPH Catheter System for minimally invasive treatment of benign prostatic hyperplasia.

Introduction: Benign Prostatic Hyperplasia (BPH) can lead to Lower Urinary Tract Symptoms (LUTS) that worsen with age and impact quality of life. Minimally invasive Surgical Therapies (MISTs) provide an alternative to medical and surgical interventions for the treatment of LUTS. The Optilume BPH Catheter System is a MIST for LUTS, which is the focus of this review.

Areas covered: The Optilume BPH Catheter System is a Food and Drug Administration (FDA)-approved MIST that utilizes balloon dilation and delivery of paclitaxel to the prostatic urethra to treat LUTS. This review evaluates the technology, utility, clinical evidence, safety profile, and long-term efficacy of Optilume BPH Catheter System, in the context of alternative options for management of LUTS. PubMed and Google Scholar were searched and all published articles and abstracts up to May 2025 related to Optilume BPH Catheter Systems were included in our review.

Expert opinion: The Optilume BPH Catheter System is a promising MIST in the market with durable results and acceptable safety profile. Ongoing and future research will further refine its long-term safety and efficacy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信